CD53 and carcinoma: investigated the increase in five cell surface antigen proteins (including Fas, MHC-I, ICAM-1, CEA, or mucin-1) post-RT in 23 human carcinoma cell lines and the results suggested that 91% of human carcinoma cell lines showed dose-dependent increases in at least one antigen (201).